Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

BioCorRx (BICX) Asset Writedowns and Impairment (2016 - 2023)

BioCorRx (BICX) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with $47980.0 as the latest value for Q1 2023.

Quarterly Asset Writedowns and Impairment changed N/A to $47980.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $47980.0 through Dec 2023, changed N/A year-over-year, with the annual reading at $47980.0 for FY2023, N/A changed from the prior year.
Asset Writedowns and Impairment hit $47980.0 in Q1 2023 for BioCorRx, up from $3400.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $47980.0 in Q1 2023 to a low of -$1000.0 in Q1 2019.